DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Anoma Ranaweera B.V.Sc; PhD (Clinical Biochemistry, University of Liverpool, UK), 2013.
On August 26, 2013, the U. S. Food and Drug Administration (FDA) approved brimonidine (Mirvaso®) topical gel, 0.33%* (Galderma Laboratories, Texas, USA) for the topical treatment of persistent (non-transient) facial erythema (redness) of rosacea in adults 18 years of age or older.
It is the first and only FDA-approved topical treatment specifically developed and indicated for persistent facial erythema in rosacea.
The approval of brimonidine topical gel was based on data collected from more than 550 patients enrolled in two phase 3 clinical studies, each of one-month duration. The results from both studies showed that adults who used Mirvaso demonstrated significantly greater improvement in the facial redness of rosacea than vehicle gel. In addition, a long-term study in 276 subjects who used brimonidine topical gel for up to 12-months was also conducted.
Key efficacy findings are summarised in the table and figures below.
|Success*||Study 1||Study 2|
|Mirvaso® topical gel (N=129)||Vehicle gel (N=131)||Mirvaso® topical gel (N=148)||Vehicle gel (N=145)|
*2-grade improvement on CEA and 2-grade improvement on PSA scale on day 29
Adverse reactions reported in 330 individuals treated with topical brimonidine gel applied once daily for 29 days are summarised in the table below.
|Mirvaso® topical gel (N=330) No. patients (%)||Vehicle gel (N=331) No. patients (%)|
|Erythema||12 (4%)||3 (1%)|
|Skin burning sensation||5 (2%)||2 (1%)|
|Dermatitis||3 (1%)||1 (<1%)|
|Paraesthesia (tingling/prickly)||2 (1%)||1 (<1%)|
|Acne||2 (1%)||1 (<1%)|
|Vision blurred||2 (1%)||0|
|Nasal congestion||2 (1%)||0|
If you are not based in New Zealand, we suggest you refer to your national drug approval agency for further information about medicines (eg, the Australian Therapeutic Goods Administration and the US Food and Drug Administration) or a national or state-approved formulary (eg, the New Zealand Formulary and New Zealand Formulary for Children and the British National Formulary and British National Formulary for Children).
National Rosacea Society
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.